Amicus Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $141,517 | $126,669 | $110,403 | $115,082 |
Gross Profit | 128,238 | 113,226 | 94,682 | 101,576 |
EBITDA | 21,647 | 14,802 | -28,993 | -16,651 |
EBIT | 19,477 | 12,620 | -31,147 | -18,833 |
Net Income | -6,729 | -15,697 | -48,419 | -33,843 |
Net Change In Cash | 141,517 | 126,669 | 110,403 | 115,082 |
Free Cash Flow | -23,327 | 21,593 | -31,506 | 1,727 |
Cash | 233,647 | 209,335 | 209,761 | 246,994 |
Basic Shares | 304,690 | 303,773 | 302,903 | 293,594 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $399,356 | $329,233 | $305,514 | $260,886 |
Gross Profit | 362,030 | 290,634 | 271,048 | 229,842 |
EBITDA | -92,079 | -199,578 | -202,874 | -242,983 |
EBIT | -99,952 | -204,920 | -209,083 | -251,829 |
Net Income | -151,584 | -236,568 | -250,460 | -276,852 |
Net Change In Cash | 399,356 | 329,233 | 305,514 | 260,886 |
Cost of Revenue | -81,722 | 88,343 | 15,989 | |
Free Cash Flow | -76,531 | -170,341 | -206,375 | -236,517 |
Cash | 246,994 | 148,813 | 245,197 | 163,240 |
Basic Shares | 295,164 | 289,057 | 271,421 | 258,867 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.02 |
2024-06-30 | -$0.05 |
2024-03-31 | -$0.16 |
2023-12-31 | -$0.11 |
